cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Revance Therapeutics Inc
6 own
8 watching
Current Price
$31.06
$0.65
(2.14%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
2,609.57M
52-Week High
52-Week High
37.98
52-Week Low
52-Week Low
11.27
Average Volume
Average Volume
0.92M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization2,609.57M
icon52-Week High37.98
icon52-Week Low11.27
iconAverage Volume0.92M
iconDividend Yield--
iconP/E Ratio--
What does the Revance Therapeutics Inc do?
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacturing, and commercialization of novel botulinum toxin products for various aesthetic and therapeutic indications. The company's lead drug candidate is DaxibotulinumtoxinA for injection (RT002), which is in Phase III clinical trials to treat glabellar (frown) lines, as well as in Phase II clinical trials for the treatment of cervical dystonia and plantar fasciitis. It is also developing DaxibotulinumtoxinA topical gel (RT001) that is in preclinical development. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was founded in 1999 and is headquartered in Newark, California.
Read More
How much money does Revance Therapeutics Inc make?
News & Events about Revance Therapeutics Inc.
Zolmax
2 months ago
Revance Therapeutics, Inc. (NASDAQ:RVNC Get Rating) President Dustin S. Sjuts sold 21,508 shares of the companys stock in a transaction that occurred on Thursday, March 9th. The stock was sold at an average price of $31.59, for a total value of $679,437.72. Following the sale, the president now owns...
PR Newswire
3 months ago
Facial Injectable Global Market Report 2022: Sector to Reach $23.55 Billion by 2027 at a 15.46% CAGR Facial Injectable Global Market Report 2022: Sector to Reach $23.55 Billion by 2027 at a 15.46% CAGR PR Newswire DUBLIN, Feb. 28, 2023 DUBLIN, Feb. 28, 2023 /PRNewswire/ -- The 'Facial...
Business Wire
3 months ago
Revance Therapeutics, Inc. (RVNC), today announced that the company will participate in the 43rd Annual Cowen Healthcare Conference, taking place March 6-8, 2023, in Boston, Massachusetts. President, Dustin S. Sjuts, and Chief Financial Officer, Tobin Schilke, are scheduled to participate in a...
Business Wire
3 months ago
Revance Therapeutics, Inc. (RVNC) today announced that new data on DAXXIFY will be presented at the annual meeting of Association of Academic Physiatrists (AAP), taking place in Anaheim, California, February 21-24, 2023. The supplemental biologics license agreement for DAXXIFY for the treatment of...
Ticker Report
3 months ago
StockNews.com lowered shares of Revance Therapeutics (NASDAQ:RVNC Get Rating) from a hold rating to a sell rating in a report issued on Thursday. RVNC has been the topic of several other reports. Barclays boosted their price target on Revance Therapeutics from $35.00 to $37.00 and gave the ...
Frequently Asked Questions
Frequently Asked Questions
What is Revance Therapeutics Inc share price today?
plus_minus_icon
Can Indians buy Revance Therapeutics Inc shares?
plus_minus_icon
How can I buy Revance Therapeutics Inc shares from India?
plus_minus_icon
Can Fractional shares of Revance Therapeutics Inc be purchased?
plus_minus_icon
What are the documents required to start investing in Revance Therapeutics Inc stocks?
plus_minus_icon
What is today’s traded volume of Revance Therapeutics Inc?
plus_minus_icon
What is today’s market capitalisation of Revance Therapeutics Inc?
plus_minus_icon
What is the 52-Week High and Low Range of Revance Therapeutics Inc?
plus_minus_icon
What percentage is Revance Therapeutics Inc down from its 52-Week High?
plus_minus_icon
What percentage is Revance Therapeutics Inc up from its 52-Week Low?
plus_minus_icon
Current Price
$31.06
$0.65
(2.14%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc.
$38.26
$1.25 (3.38 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$58.22
$1.43 (2.52 %)
Galapagos NV
Galapagos NV
$41.46
$0.46 (1.12 %)
Sage Therapeutics Inc
Sage Therapeutics Inc
$49.82
$0.26 (0.52 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc.
$38.26
$1.25 (3.38 %)
Blueprint Medicines Corp
Blueprint Medicines Corp
$58.22
$1.43 (2.52 %)
Galapagos NV
Galapagos NV
$41.46
$0.46 (1.12 %)
Sage Therapeutics Inc
Sage Therapeutics Inc
$49.82
$0.26 (0.52 %)
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00